$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000156459020006889 Filed on February 27, 2020

Income Statement

Concept	2020 Q1	2018 Q4	2018 Q3
Revenue	$90.07M	$59.57M	$58.31M
YoY Change	43.06%	36.75%	63.88%
Cost Of Revenue	$5.000M	$4.400M	$3.839M
YoY Change	69.49%	18.92%	19.97%
Gross Profit	$87.27M	$56.75M	$54.47M
YoY Change	45.43%	38.05%	62.86%
Gross Profit Margin	96.89%	95.26%	93.42%
Selling, General & Admin	$102.0M	$74.30M	$61.10M
YoY Change	9.54%	13.44%	-0.81%
% of Gross Profit	116.85%	130.93%	112.18%
Research & Development	$72.64M	$48.20M	$53.10M
YoY Change	37.25%	11.57%	45.88%
% of Gross Profit	83.23%	84.94%	97.49%
Depreciation & Amortization	$294.0K	$780.0K	$760.0K
YoY Change	-29.16%	9.86%	10.14%
% of Gross Profit	0.34%	1.37%	1.4%
Operating Expenses	$174.6M	$122.4M	$114.2M
YoY Change	19.58%	12.6%	16.53%
Operating Profit	-$89.52M	-$65.65M	-$61.27M
YoY Change	2.15%	-2.87%	-5.09%
Interest Expense	$3.000M	$1.700M	$1.229M
YoY Change	2.25%	54.55%	11.73%
% of Operating Profit
Other Income/Expense, Net	$1.497M	$100.0K	-$1.720M
YoY Change	553.71%
Pretax Income	-$88.00M	-$65.50M	-$61.76M
YoY Change	3.62%	-3.39%	-4.39%
Income Tax	$0.00	$0.00	$376.0K
% Of Pretax Income
Net Earnings	-$88.02M	-$65.49M	-$62.14M
YoY Change	3.19%	-4.91%	-4.77%
Net Earnings / Revenue	-97.73%	-109.94%	-106.57%
Basic Earnings Per Share
Diluted Earnings Per Share	-$566.3K	-$497.3K	-$496.8K
COMMON SHARES
Basic Shares Outstanding	155.3M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2018 Q4	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$651.4M	$473.5M	$214.1M
YoY Change	57.22%	38.72%	-41.6%
Cash & Equivalents	$173.1M	$134.8M	$63.90M
Short-Term Investments	$478.3M	$338.8M	$150.2M
Other Short-Term Assets	$22.10M	$20.70M	$15.00M
YoY Change	-6.75%	143.53%	2.74%
Inventory	$6.318M	$4.070M	$4.300M
Prepaid Expenses		$20.73M
Receivables	$41.60M	$26.09M	$20.00M
Other Receivables	$3.000M	$1.700M	$700.0K
Total Short-Term Assets	$724.4M	$526.1M	$254.1M
YoY Change	52.06%	40.87%	-36.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.70M	$3.309M	$3.400M
YoY Change	266.6%	24.31%	13.33%
Goodwill
YoY Change
Intangibles		$4.062M	$4.431M
YoY Change		-26.65%
Long-Term Investments
YoY Change
Other Assets	$7.100M	$1.899M	$4.500M
YoY Change	353.67%	436.44%	60.71%
Total Long-Term Assets	$23.10M	$14.10M	$12.40M
YoY Change	-6.47%	27.81%	5.98%
TOTAL ASSETS
Total Short-Term Assets	$724.4M	$526.1M	$254.1M
Total Long-Term Assets	$23.10M	$14.10M	$12.40M
Total Assets	$747.5M	$540.2M	$266.5M
YoY Change	49.17%	40.49%	-35.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.600M	$3.167M	$3.000M
YoY Change	101.53%	-63.95%	0.0%
Accrued Expenses	$93.12M	$56.40M	$38.90M
YoY Change	29.86%	40.14%	17.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$99.70M	$59.57M	$41.80M
YoY Change	32.93%	21.49%	15.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$9.300M	$1.558M	$1.200M
YoY Change	818.97%	679.0%	500.0%
Total Long-Term Liabilities	$9.300M	$1.558M	$1.200M
YoY Change	818.97%	715.71%	500.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$99.70M	$59.57M	$41.80M
Total Long-Term Liabilities	$9.300M	$1.558M	$1.200M
Total Liabilities	$109.1M	$61.12M	$43.00M
YoY Change	31.84%	24.18%	18.13%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.469B
YoY Change		20.04%
Common Stock		$1.948B
YoY Change		24.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$638.4M	$479.1M	$223.4M
YoY Change
Total Liabilities & Shareholders Equity	$747.5M	$540.2M	$266.5M
YoY Change	49.17%	40.49%	-35.58%

Cashflow Statement

Concept	2020 Q1	2018 Q4	2018 Q3
OPERATING ACTIVITIES
Net Income	-$88.02M	-$65.49M	-$62.14M
YoY Change	3.19%	-4.91%	-4.77%
Depreciation, Depletion And Amortization	$294.0K	$780.0K	$760.0K
YoY Change	-29.16%	9.86%	10.14%
Cash From Operating Activities	-$49.00M	-$39.08M	-$42.28M
YoY Change	-23.64%	31.14%	-27.73%
INVESTING ACTIVITIES
Capital Expenditures	-$930.0K	-$570.0K	-$1.020M
YoY Change	-213.14%		1600.0%
Acquisitions
YoY Change
Other Investing Activities	$30.54M	-$188.4M	$32.80M
YoY Change	29.52%	941.92%	69.16%
Cash From Investing Activities	$29.61M	-$189.0M	$31.78M
YoY Change	30.1%	943.92%	64.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$298.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.754M	300.6M	210.0K
YoY Change	-10.11%	6175.78%	-97.34%
NET CHANGE
Cash From Operating Activities	-49.00M	-39.08M	-42.28M
Cash From Investing Activities	29.61M	-189.0M	31.78M
Cash From Financing Activities	3.754M	300.6M	210.0K
Net Change In Cash	-15.64M	72.58M	-10.29M
YoY Change	-58.01%	-268.36%	-67.08%
FREE CASH FLOW
Cash From Operating Activities	-$49.00M	-$39.08M	-$42.28M
Capital Expenditures	-$930.0K	-$570.0K	-$1.020M
Free Cash Flow	-$48.07M	-$38.51M	-$41.26M
YoY Change	-26.04%	29.23%	-29.4%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:ProductMember
CY2018	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:ProductMember
CY2019	us-gaap	Lessee Operating Lease Existence Of Option To Extend LesseeOperatingLeaseExistenceOfOptionToExtend	true
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2019	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm1	P6Y6M
CY2019	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Weighted Average Remaining Contractual Term1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm1	P8Y6M
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:AccruedLiabilitiesCurrent
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2019Q2	dei	Entity Public Float EntityPublicFloat	2200000000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189680000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	507749000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35781000
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	2093000
CY2019Q4	us-gaap	Inventory Net InventoryNet	6341000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18606000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	760250000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	526106000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3180000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9524000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2585000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4062000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4787000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4826000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2857000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1899000
CY2019Q4	us-gaap	Assets Assets	783183000
CY2018Q4	us-gaap	Assets Assets	540202000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7222000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3167000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	67604000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56398000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74826000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	59565000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6361000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2861000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1558000
CY2019Q4	us-gaap	Liabilities Liabilities	84048000
CY2018Q4	us-gaap	Liabilities Liabilities	61123000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12377000
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2019	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC
CY2018	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2017	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2019	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:ProductMember
CY2019	dei	Trading Symbol TradingSymbol	ACAD
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	000-50768
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1376651
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2019	dei	City Area Code CityAreaCode	858
CY2019	dei	Local Phone Number LocalPhoneNumber	558-2871
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	155339667
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134758000
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	338762000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26090000
CY2018Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1699000
CY2018Q4	us-gaap	Inventory Net InventoryNet	4070000
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	20727000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	265758000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	255062000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	187163000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	11344000
CY2019	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	8254000
CY2017	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	3983000
CY2018	acad	License Fees And Royalty Expense LicenseFeesAndRoyaltyExpense	5953000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	240385000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149189000
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	417311000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3309000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	223807000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	339076000
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9077000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-289403000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	572103000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	327914000
CY2017	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	478818000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-217757000
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	413927000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	261678000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1129000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2148000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165836000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	27000
CY2019Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	507465000
CY2019Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	335000
CY2019Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	51000
CY2019Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	507749000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4206000
CY2019	acad	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-2518000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1497000
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1367000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-151130000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26665000
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4522000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-505000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	11165000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-243936000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-288284000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1119000
CY2017	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-150000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1926000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1012000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-39000
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.36
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.94
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	155275300
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	155275300
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	143853597
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	143853597
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	15000
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	14000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2402945000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1948300000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1704122000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1468863000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	297000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-372000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	699135000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	479079000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	783183000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	540202000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	124901000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	325638000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	585621000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	471251000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-246545000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-247444000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-292410000
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5348000
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	4126000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	997000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1840000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-234383000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	876000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1256000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-245192000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-289403000
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.60
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	147199000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	126583000
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	122600000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-245192000
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	667000
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	24000
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-499000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-234590000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-245165000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92473000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	371847000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	306647000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31188000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	371847000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	306647000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31188000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-289908000
CY2019	us-gaap	Profit Loss ProfitLoss	-235259000
CY2018	us-gaap	Profit Loss ProfitLoss	-245192000
CY2017	us-gaap	Profit Loss ProfitLoss	-289403000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	82265000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	81564000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	75532000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	3613000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	578000
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	291000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1477000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1476000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1477000
CY2019	us-gaap	Gain Loss On Investments GainLossOnInvestments	997000
CY2018	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1840000
CY2019	us-gaap	Depreciation Depreciation	1289000
CY2018	us-gaap	Depreciation Depreciation	1529000
CY2017	us-gaap	Depreciation Depreciation	1236000
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000
CY2018	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-88000
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-4000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9691000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8747000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11440000
CY2019	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	394000
CY2018	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	612000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1737000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2121000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12270000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	911000
CY2019	acad	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-3875000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	236000
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-431000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4055000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5619000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4874000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6458000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15994000
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2644000
CY2017	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	34000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-167470000
CY2019	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	578634000
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Equity PaymentsToAcquireAvailableForSaleSecuritiesEquity	3149000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	44000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	812000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71489000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-6000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	82265000
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81564000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75532000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19516000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20824000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	54883000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	67691000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-94102000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	139584000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	71893000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	165995000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194467000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	139584000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	71893000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1597000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1261000
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1367000
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	34000
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	160000
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	9000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	518411000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-289403000
CY2017	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	-289000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75884000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	335285000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	298537000
CY2018	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	4428000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3682000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-245192000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82312000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	479079000
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	271452000
CY2019	acad	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Units Releases StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockUnitsReleases	95984000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4411000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	82799000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	669000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	699135000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p>
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134758000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	189680000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	69418000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134758000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4826000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4787000
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2475000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4826000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	139584000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	194467000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	71893000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	139584000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18526000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2019	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0
CY2018	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	100000
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	1100000
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	2700000
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	700000
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2019	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2018	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2017	acad	Number Of Large Customers NumberOfLargeCustomers	4
CY2016Q2	acad	Regulatory Milestone Payment RegulatoryMilestonePayment	8000000.0
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8000000.0
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1500000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1500000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000000.0
CY2019	us-gaap	Advertising Expense AdvertisingExpense	38300000
CY2018	us-gaap	Advertising Expense AdvertisingExpense	39800000
CY2017	us-gaap	Advertising Expense AdvertisingExpense	15600000
CY2018Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2019Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	0
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration Risk</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, investment securities, accounts receivable, and restricted cash. The Company invests its excess cash primarily in money market funds, U.S. treasury notes, and high quality, marketable debt instruments of corporations and government sponsored enterprises in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve principal and maintain liquidity. All investment securities have a credit rating of at least A3/A- or better, or P-1/A-1 or better, as determined by Moody’s Investors Service or Standard & Poor’s. Further, the Company specifies credit quality standards for its customers that are designed to limit the Company’s credit exposure to any single party.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not currently have any of its own manufacturing facilities, and therefore it depends on an outsourced manufacturing strategy for the production of NUPLAZID for commercial use and for the production of its product candidates for clinical trials. The Company has contracts in place with two third-party manufacturers of commercial drug product and one third-party manufacturer of drug substance that is approved for the production of NUPLAZID active pharmaceutical ingredient (“API”). Although there are potential sources of supply other than the Company’s existing suppliers, any new supplier would be required to qualify under applicable regulatory requirements.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into distribution agreements with a limited number of SPs and SDs, and all of the Company’s product sales are to these customers. For the year ended December 31, 2019, the Company’s four largest customers represented approximately 77% of the Company’s product revenue and 75% of the Company’s accounts receivable balance at December 31, 2019. For the year ended December 31, 2018, the Company’s four largest customers represented approximately 85% of the Company’s product revenue and 84% of the Company’s accounts receivable balance at December 31, 2018. For the year ended December 31, 2017, the Company’s four largest customers represented approximately 89% of the Company’s product revenue and 87% of the Company’s accounts receivable balance at December 31, 2017.</p>
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7514000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5332000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4205000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3180000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3309000
CY2019	us-gaap	Depreciation Depreciation	1300000
CY2018	us-gaap	Depreciation Depreciation	1500000
CY2017	us-gaap	Depreciation Depreciation	1200000
CY2019	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	200000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	28.22
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3880757
CY2018Q4	acad	Debt Securities And Equity Securities Fv Ni Amortized Cost DebtSecuritiesAndEquitySecuritiesFvNiAmortizedCost	339145000
CY2018Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Gains DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedGains	39000
CY2018Q4	acad	Debt Securities And Equity Securities Fv Ni Unrealized Losses DebtSecuritiesAndEquitySecuritiesFvNiUnrealizedLosses	422000
CY2018Q4	acad	Debt Securities And Equity Securities Fv Ni DebtSecuritiesAndEquitySecuritiesFvNi	338762000
CY2019Q4	acad	Available For Sale Securities Debt Maturities Rolling Year One Through Two AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwo	24300000
CY2018Q4	acad	Available For Sale Securities Debt Maturities Rolling Year One Through Two AvailableForSaleSecuritiesDebtMaturitiesRollingYearOneThroughTwo	31800000
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	20
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	57
CY2019Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	220834000
CY2019Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	51000
CY2019Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	220834000
CY2019Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	51000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	242961000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	208000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	44637000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	214000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	287598000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	422000
CY2019Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	623123000
CY2018Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	451365000
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3175000
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1110000
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1685000
CY2018Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	483000
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1481000
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2477000
CY2019Q4	us-gaap	Inventory Net InventoryNet	6341000
CY2018Q4	us-gaap	Inventory Net InventoryNet	4070000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8512000
CY2017	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	400000
CY2018	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	1600000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21080000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17028000
CY2019Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	14273000
CY2018Q4	acad	Accrued Clinical Development Services Current AccruedClinicalDevelopmentServicesCurrent	10367000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	13691000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	19325000
CY2019Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	11326000
CY2018Q4	acad	Accrued Sales Allowances Current AccruedSalesAllowancesCurrent	5849000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3434000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1971000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1200000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1829000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2629000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	67604000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	56398000
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	271500000
CY2019Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7187500
CY2018Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	298500000
CY2018Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	18602941
CY2016Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	215900000
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6969696
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	281600000
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10344827
CY2012Q4	acad	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	80500000
CY2012Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	19000000
CY2012Q4	acad	Equity Issuance Per Share Amount1 EquityIssuancePerShareAmount1	4.43
CY2012Q4	acad	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	500000
CY2012Q4	acad	Issuance Of Warrants Price Per Share IssuanceOfWarrantsPricePerShare	4.42
CY2012Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2012Q4	acad	Issuance Of Warrants Value IssuanceOfWarrantsValue	2200000
CY2019	acad	Description Of Warrant DescriptionOfWarrant	Per their terms, the warrants to purchase 500,000 shares of common stock, of which 493,145 remained outstanding at December 31, 2019, may not be exercised if the holder’s ownership of the Company’s common stock would exceed 19.99 percent following such exercise.
CY2012Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	500000
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	493145
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19868781
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.04
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3502129
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-110972000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-165824000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.73
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2062925
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	29.10
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17427228
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.69
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	247336000
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	8622679
CY2019Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageExercisePrice	30.18
CY2019Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue1	109605000
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	8804549
CY2019Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageExercisePrice	27.23
CY2019Q4	acad	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Intrinsic Value1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedIntrinsicValue1	137731000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8622679
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.18
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	109605000
CY2019	acad	Closing Market Price Of Common Stock ClosingMarketPriceOfCommonStock	42.78
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	56600000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	11200000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	24400000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000000.0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.97
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.14
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	21.11
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	119300000
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.05
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	4300000
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3600000
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	3300000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-123411000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-78112000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-45249000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-243035000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-234383000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-243936000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-288284000
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	900000
CY2018	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1300000
CY2017	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1100000
CY2019Q4	acad	Federal Research And Development Credit Carryforwards FederalResearchAndDevelopmentCreditCarryforwards	40400000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	182948000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	170476000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	48069000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32984000
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7607000
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7421000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	45440000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	45492000
CY2019Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	59783000
CY2019Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	18303000
CY2018Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	8530000
CY2019Q4	acad	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	2366000
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	8568000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6220000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	373084000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	271123000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	370783000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	271123000
CY2019Q4	acad	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	2301000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2301000
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	99700000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019Q4	acad	Deferred Tax Asset Switzerland Tax Reform DeferredTaxAssetSwitzerlandTaxReform	57000000.0
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-49365000
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-51226000
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-98016000
CY2019	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	6070000
CY2018	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	3432000
CY2017	acad	Income Tax Expense Permanent Tax Differences IncomeTaxExpensePermanentTaxDifferences	1341000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	16687000
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	7941000
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5573000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	99846000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	34333000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-28230000
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2138000
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1017000
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-26000
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	1861000
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	2938000
CY2017	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	360000
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	20413000
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	20896000
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	61480000
CY2017	acad	Income Tax Reconciliation Tax Cuts And Jobs Act IncomeTaxReconciliationTaxCutsAndJobsAct	68889000
CY2019	acad	Income Tax Reconciliation Switzerland Tax Reform IncomeTaxReconciliationSwitzerlandTaxReform	-59181000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	57000
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-159000
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	894000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	876000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1256000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1119000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1900000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3100000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	400000
CY2017	us-gaap	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit	1100000
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2019	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	0
CY2018	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	0
CY2017	us-gaap	Income Tax Examination Penalties Expense IncomeTaxExaminationPenaltiesExpense	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5037000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1933000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2664000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1908000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3104000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	361000
CY2017	us-gaap	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Existing Income Tax Expense Benefit TaxCutsAndJobsActOf2017IncompleteAccountingExistingIncomeTaxExpenseBenefit	-1092000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6945000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5037000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1933000
CY2019	acad	Lease Expiration Month And Year LeaseExpirationMonthAndYear	2031-02
CY2018Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	0
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2019	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	The Company leases facilities and certain equipment under noncancelable operating leases with remaining lease terms of 0.3 year to 6.1 years, one of which includes an option to extend the lease for one five-year term.
CY2019	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	one of which includes an option to extend the lease for one five-year term.
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	5155000
CY2018	us-gaap	Operating Lease Cost OperatingLeaseCost	4503000
CY2017	us-gaap	Operating Lease Cost OperatingLeaseCost	3828000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	4841000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	13399000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3434000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6361000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9795000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3563000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2660000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2089000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1192000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1080000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1011000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11595000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1800000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9795000
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4770000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4170000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6906000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	7181000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	6568000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	38683000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	68278000
CY2019Q1	us-gaap	Revenues Revenues	62959000
CY2019Q2	us-gaap	Revenues Revenues	83205000
CY2019Q3	us-gaap	Revenues Revenues	94586000
CY2019Q4	us-gaap	Revenues Revenues	98326000
CY2019	us-gaap	Revenues Revenues	339076000
CY2019Q1	us-gaap	Gross Profit GrossProfit	60009000
CY2019Q2	us-gaap	Gross Profit GrossProfit	80247000
CY2019Q3	us-gaap	Gross Profit GrossProfit	92170000
CY2019Q4	us-gaap	Gross Profit GrossProfit	95306000
CY2019	us-gaap	Gross Profit GrossProfit	327732000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-85304000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-54941000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-41978000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-53036000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-235259000
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.60
CY2018Q1	us-gaap	Revenues Revenues	48868000
CY2018Q2	us-gaap	Revenues Revenues	57063000
CY2018Q3	us-gaap	Revenues Revenues	58305000
CY2018Q4	us-gaap	Revenues Revenues	59571000
CY2018	us-gaap	Revenues Revenues	223807000
CY2018Q1	us-gaap	Gross Profit GrossProfit	46715000
CY2018Q2	us-gaap	Gross Profit GrossProfit	53501000
CY2018Q3	us-gaap	Gross Profit GrossProfit	54466000
CY2018Q4	us-gaap	Gross Profit GrossProfit	56748000
CY2018	us-gaap	Gross Profit GrossProfit	211430000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-54296000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-63266000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-62138000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-65492000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-245192000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.94

Files In Submission

Name	View Source	Status
0001564590-20-006889-index-headers.html	Edgar Link	pending
0001564590-20-006889-index.html	Edgar Link	pending
0001564590-20-006889.txt	Edgar Link	pending
0001564590-20-006889-xbrl.zip	Edgar Link	pending
acad-10k_20191231.htm	Edgar Link	pending
acad-10k_20191231_htm.xml	Edgar Link	completed
acad-20191231.xsd	Edgar Link	pending
acad-20191231_cal.xml	Edgar Link	unprocessable
acad-20191231_def.xml	Edgar Link	unprocessable
acad-20191231_lab.xml	Edgar Link	unprocessable
acad-20191231_pre.xml	Edgar Link	unprocessable
acad-ex211_8.htm	Edgar Link	pending
acad-ex231_10.htm	Edgar Link	pending
acad-ex311_6.htm	Edgar Link	pending
acad-ex312_54.htm	Edgar Link	pending
acad-ex321_12.htm	Edgar Link	pending
acad-ex322_55.htm	Edgar Link	pending
acad-ex43_475.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gkxxj1gwvjut000001.jpg	Edgar Link	pending
gkxxj1gwvjut000002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2020 Q1 Form 10-K Financial Statement

#000156459020006889 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2020 Q1 Form 10-K Financial Statement

#000156459020006889 Filed on February 27, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad